FROM Kevin Davies
Genome Companies Dominate the Southland Last week, we talked about the development of genome sequencing , which took 10 years and $2 billion twenty years ago. Since then, it’s developed at an astonishing pace, centered in Southern California. Kevin Davies is editor-in-chief of Bio-IT World and author of The $1000 Genome : The Revolution in DNA Sequencing and the New Era of Personalized Medicine.
The $1,000 Genome and 'Personalized Medicine' It took $2 billion and ten years to complete the Human Genome Project . Now, just ten years later, many individuals have had their genomes sequenced, and the cost keeps dropping. Kevin Davies is editor of Bio-IT World , which covers the role of technology in the life sciences. He's also the author of The $1000 Genome : The Revolution in DNA Sequencing and the New Era of Personalized Medicine.
Trump plays scolder-in-chief with NATO allies At the opening of NATO’s dramatic new headquarters in Brussels today, President Trump acknowledged that Article 5 — promising that “an attack on one nation is an attack on all” -- has only been invoked one time: in the aftermath of September 11. But the President failed to provide what 27 other Alliance members have been waiting for: a re-commitment by America’s new leader to Article 5. Instead, they got a scolding.
Venezuela spirals into economic and political chaos Venezuela, a country whose potential for prosperity is unmatched, finds itself on the verge of civil war. What sustains the repressive government? With time running out, guest host León Krauze looks at what the international community can do to pull the country from the edge of collapse.
Trump's new look at civil rights and global warming President Trump is reportedly ready to pull the US out of the Paris Agreement on Climate Change. We look at the possible consequences. On the second half of the program, we hear about cuts in Obama-Era civil rights programs called for by the Trump Administration's first budget plan.
Will the Senate write a healthcare bill in secret? While Democrats and Republicans argue White House relations with Russia, another question is being decided behind closed doors: who gets help buying health insurance and who doesn't? We hear how the pros and cons are being shrouded in secrecy.